about
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsOptimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.Spontaneous rupture of non-parasitic hepatic cyst.Molecule-targeted agents in endometrial cancer.AVE8062: a new combretastatin derivative vascular disrupting agent.Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Molecular features and clinical outcome of lung malignancies in very young people.Percutaneous ultrasound-guided radiofrequency thermal ablation of malignant osteolyses.Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung.Radiofrequency ablation combined with percutaneous ethanol injection in the treatment of hepatocellular carcinoma and portal vein neoplastic thrombosis.Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.Scrotal involvement in Madelung disease: clinical, ultrasound and MR findings.Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.Safety of Systemic Chemotherapy in a Patient With Mitochondrial Myopathy and Non–Small-Cell Lung CancerComplications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liverHepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma
P50
Q28247372-DA57CD9D-DACD-4DD3-949E-A902063DC5A8Q33395415-572F5FEC-53B7-4213-BF19-17AF0FBEF53AQ33419744-19DBF8F4-9453-4C08-AC04-03B8548799A6Q33420524-ADA18A73-8D3E-4C7D-99EF-E8A2792FA294Q35016510-6430064E-6291-4CF7-9865-F5BC6C07F1FCQ36070099-274A5D2B-A150-49B0-9C69-8FAE4C05D039Q36367013-2E43C71F-4AE3-4DBC-B08A-A97FBA11D4E9Q37357757-5E24BB65-35A0-4B07-A6BA-98B3260EC151Q37598267-57F3E76F-EA22-4547-AA73-7D4AAE15974EQ37698208-BA856EC3-D447-4B63-B7FD-731A9C58C0B3Q37988235-3F48F0A9-0CA1-4071-89BF-E6240B0B7455Q38051475-1CF5DA29-BEA3-4D80-BE68-3F51BEE5C548Q38155286-48FB8637-E8AC-4E82-9EB4-DAC771154879Q38582589-062B450D-31A4-438F-8E4D-184A9D7DE007Q39022545-6F1CFB64-B8BB-448C-BFA1-28661660642CQ39384016-11CE760D-6201-40B2-9130-ED4059B6205AQ40512867-DB507077-68EA-4E7A-8DBA-02C61C4B775AQ41002619-28BA2A8F-A43F-4F55-A9A4-DCBD9AB45902Q41015110-ECC0F63F-9DE4-4B70-A723-AE83A5FAFFABQ41929007-FF8B0DA5-D89D-45DD-B86D-6CC9DF119A78Q43084809-D38EA653-4CA5-46AD-B71E-60BAF308BE43Q43514757-CF3D815A-A1B1-41CF-9E8E-EBC7FAE379C6Q45031028-028623E0-EF9D-4FFE-9998-AABBC94671D0Q46455772-43C154A3-5365-4963-BE9F-130A2EF247ECQ46587807-B083303C-7F8C-42FA-A575-BFAAB6F58475Q46919696-E8FD635D-742E-41A2-9368-9382D9E42A66Q47739944-AB411B5A-A212-4977-94BE-D90C71986D44Q50496257-BABF125A-4255-411A-B609-1649737D54F6Q52641965-5ECE0850-8D2F-4A30-A743-7813EF2CEA69Q52839850-28019BD2-8A4C-4FDD-BE2C-5DAFA52B8E93Q61943859-83BA14B3-3FA7-40FE-BD0B-B1F5DFD8011EQ80789216-8574A613-0898-4C3F-8232-68963147FF4BQ82645814-FC0A4409-C192-4F93-8D78-3F738BE9A265
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Delmonte
@ast
Angelo Delmonte
@en
Angelo Delmonte
@es
Angelo Delmonte
@nl
type
label
Angelo Delmonte
@ast
Angelo Delmonte
@en
Angelo Delmonte
@es
Angelo Delmonte
@nl
prefLabel
Angelo Delmonte
@ast
Angelo Delmonte
@en
Angelo Delmonte
@es
Angelo Delmonte
@nl
P106
P21
P31
P496
0000-0001-9065-6123